SCNI Scinai Immunotherapeutics Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY99.2%
TTM net income YoY-273.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-202.3%
Operating margin-575.3%
Net margin-633.6%
FCF margin-461.9%
EBITDA margin-466.9%
Returns
ROE-91.9%
ROA-66.3%
ROIC (approx.)-82.4%
Asset turnover0.10x
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.31M | $658,000 |
| Cost of revenue | $3.96M | $1.24M |
| Gross profit | -$2.65M | -$580,000 |
| R&D expense | $2.37M | $5.53M |
| SG&A expense | $2.52M | $2.53M |
| Operating income | -$7.54M | -$8.64M |
| Net income | -$8.31M | $4.80M |
| EBITDA | -$6.12M | -$6.99M |
| EPS (diluted) | — | — |
| Weighted avg. shares (diluted) | 9.34B | 3.23B |
| Balance sheet | ||
| Cash & equivalents | $1.66M | $1.96M |
| Receivables | $73,000 | $83,000 |
| Current assets | $2.05M | $2.39M |
| PP&E, net | $7.79M | $9.19M |
| Total assets | $11.63M | $13.45M |
| Current liabilities | $1.58M | $1.81M |
| Total liabilities | $3.52M | $3.47M |
| Shareholders' equity | $8.10M | $9.98M |
| Shares outstanding | 13.87B | 3.41B |
| Cash flow statement | ||
| Operating cash flow | -$6.03M | -$6.33M |
| Capital expenditure | $24,000 | $12,000 |
| Free cash flow | -$6.05M | -$6.35M |
| Investing cash flow | -$24,000 | -$12,000 |
| Financing cash flow | $5.77M | $3.44M |
| Depreciation & amortization | $1.42M | $1.65M |
| Stock-based compensation | $303,000 | $682,000 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.